CAR T: Improving survival with the SoC in 2L LBCL
Symposium Resources
EBMT 2024
Cell Therapy Hub
To learn more from experts in cell therapy and access our medical education resources on demand, visit:
Symposium summary infographic
Certificate of attendance
Take part in the polls and submit your questions
Complete symposium evaluation form
▼ This medicine is subject to additional monitoring.
Adverse events should be reported. Healthcare professionals should report any adverse event via their national reporting system. In Great Britain and Northern Ireland, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app. Adverse events should also be reported to Gilead to safety_FC@gilead.com or +44 (0) 1223 897500. For other countries, click here for information on how to report adverse events.
Adverse events should be reported. Healthcare professionals should report any adverse event via their national reporting system. In Great Britain and Northern Ireland, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app. Adverse events should also be reported to Gilead to safety_FC@gilead.com or +44 (0) 1223 897500. For other countries, click here for information on how to report adverse events.